Monitoring Study Will Complement Previously Announced Clinical Development Program Of A Test For Diagnosing Tuberculosis
Xenomics, Inc. (OTCBulletin Board: XNOM; FWB:XE7), the source of next-generation medical DNAdiagnostic technologies, today announced patient enrollment has begun atItaly's National Institute for Infectious Diseases "Lazzaro Spallanzani"for a tuberculosis monitoring study using Xenomics' proprietary TransrenalDNA (Tr-DNA) diagnostic technology. [click link for full article]
(more...)
(more...)
